文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

德瑞蒂斯比值在上尿路肿瘤肾输尿管切除术后膀胱复发预测生存中的预后价值

Prognostic Value of the De Ritis Ratio in Predicting Survival After Bladder Recurrence Following Nephroureterectomy for Upper Urinary Tract Tumors.

作者信息

Yorulmaz Enis Mert, Donmez Kursad, Ozcan Serkan, Kose Osman, Gorgel Sacit Nuri, Candemir Enes, Akin Yigit

机构信息

Department of Urology, Izmir Katip Celebi University, Izmir 35620, Turkey.

Department of Urology, Ataturk Research and Training Hospital, Izmir 35360, Turkey.

出版信息

Diagnostics (Basel). 2025 Jul 22;15(15):1840. doi: 10.3390/diagnostics15151840.


DOI:10.3390/diagnostics15151840
PMID:40804804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12346446/
Abstract

: Upper tract urothelial carcinoma (UTUC) is often complicated by intravesical recurrence and cancer progression following radical nephroureterectomy (RNU). Identifying reliable prognostic biomarkers remains crucial for optimizing postoperative surveillance. The goal of this study was to assess the prognostic value of the De Ritis ratio (AST/ALT) in predicting bladder recurrence and oncologic outcomes in patients with clinically localized UTUC undergoing RNU. : This retrospective study analyzed 87 patients treated with RNU between 2018 and 2025. Preoperative De Ritis ratios were calculated, and an optimal cut-off value of 1.682 was determined using ROC analysis. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were analyzed using the Kaplan-Meier and Cox regression methods. Logistic regression was used to identify independent predictors of bladder recurrence. : A high De Ritis ratio was significantly associated with increased bladder recurrence and worse RFS and CSS, but not OS. Multivariate analysis confirmed that an elevated De Ritis ratio, current smoking, positive surgical margins, and synchronous bladder cancer were the independent predictors of bladder recurrence. The De Ritis ratio demonstrated strong discriminatory performance (AUC: 0.807), with good sensitivity and specificity for predicting recurrence. : The De Ritis ratio is a simple, cost-effective preoperative biomarker that may aid in identifying UTUC patients at higher risk for intravesical recurrence and cancer-specific mortality. Incorporating this ratio into clinical decision-making could enhance risk stratification and guide tailored follow-up strategies.

摘要

上尿路尿路上皮癌(UTUC)在根治性肾输尿管切除术(RNU)后常并发膀胱内复发和癌症进展。识别可靠的预后生物标志物对于优化术后监测仍然至关重要。本研究的目的是评估德瑞蒂斯比值(AST/ALT)在预测接受RNU的临床局限性UTUC患者膀胱复发和肿瘤学结局方面的预后价值。

这项回顾性研究分析了2018年至2025年间接受RNU治疗的87例患者。计算术前德瑞蒂斯比值,并使用ROC分析确定最佳临界值为1.682。采用Kaplan-Meier法和Cox回归法分析无复发生存期(RFS)、癌症特异性生存期(CSS)和总生存期(OS)。采用逻辑回归确定膀胱复发的独立预测因素。

高德瑞蒂斯比值与膀胱复发增加、RFS和CSS较差显著相关,但与OS无关。多因素分析证实,德瑞蒂斯比值升高、当前吸烟、手术切缘阳性和同步性膀胱癌是膀胱复发的独立预测因素。德瑞蒂斯比值表现出较强的鉴别性能(AUC:0.807),对预测复发具有良好的敏感性和特异性。

德瑞蒂斯比值是一种简单、经济有效的术前生物标志物,可能有助于识别膀胱内复发和癌症特异性死亡风险较高的UTUC患者。将该比值纳入临床决策可以加强风险分层并指导个性化的随访策略。

相似文献

[1]
Prognostic Value of the De Ritis Ratio in Predicting Survival After Bladder Recurrence Following Nephroureterectomy for Upper Urinary Tract Tumors.

Diagnostics (Basel). 2025-7-22

[2]
Impact of a novel immune and nutritional score on prognosis in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy.

J Cancer Res Clin Oncol. 2023-9

[3]
Development and validation of a nomogram based on geriatric nutritional risk index for predicting prognosis and postoperative complications in surgical patients with upper urinary tract urothelial carcinoma.

J Cancer Res Clin Oncol. 2023-12

[4]
Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China.

Int J Surg. 2025-7-3

[5]
Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.

Eur Urol. 2016-7-28

[6]
Oncological outcomes of open versus minimally invasive nephroureterectomy for locally advanced upper tract urothelial carcinoma.

World J Urol. 2025-7-23

[7]
Endoscopic intervention versus radical nephroureterectomy for the management of localized upper urinary tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies.

World J Urol. 2024-5-14

[8]
A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma.

Eur Urol. 2014-12-6

[9]
External validation of current quality care metrics after radical nephroureterectomy.

BJU Int. 2025-8

[10]
Development and external validation of a novel nomogram to predict intravesical recurrence after radical nephroureterectomy: a multicenter study.

J Cancer Res Clin Oncol. 2023-10

本文引用的文献

[1]
The role of intravesical chemotherapy following nephroureterectomy in upper tract urothelial carcinoma: A systematic review and meta-analysis.

Urol Oncol. 2025-3

[2]
Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma.

Cancer Res Treat. 2024-7

[3]
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.

Eur Urol. 2023-7

[4]
A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients-A Study of a Clinical Multicentre Database.

J Pers Med. 2022-10-27

[5]
Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma.

Eur Urol Oncol. 2022-8

[6]
Association Between Preoperative De Ritis (AST/ALT) Ratio and Oncological Outcomes Following Radical Cystectomy in Patients With Urothelial Bladder Cancer.

Clin Genitourin Cancer. 2022-4

[7]
Prognostic Role of Pretreatment De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase Ratio) in Urological Cancers: A Systematic Review and Meta-Analysis.

Front Oncol. 2020-9-4

[8]
Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy.

Urol Oncol. 2020-6

[9]
De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study.

Dis Markers. 2019-8-27

[10]
Prognostic value of aspartate transaminase to alanine transaminase (De Ritis) ratio in solid tumors: a pooled analysis of 9,400 patients.

Onco Targets Ther. 2019-7-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索